Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) fell 6.9% during mid-day trading on Thursday . The company traded as low as $6.84 and last traded at $6.7780. 99,751 shares changed hands during mid-day trading, an increase of 12% from the average session volume of 88,812 shares. The stock had previously closed at $7.28.
Analysts Set New Price Targets
A number of brokerages have recently issued reports on GYRE. Weiss Ratings downgraded shares of Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday. Zacks Research downgraded shares of Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, March 16th. Finally, Wall Street Zen downgraded shares of Gyre Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. Two investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $17.00.
Read Our Latest Analysis on GYRE
Gyre Therapeutics Trading Down 2.5%
Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) last announced its quarterly earnings data on Thursday, March 12th. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.04). Gyre Therapeutics had a positive return on equity of 3.13% and a negative net margin of 5.44%.The company had revenue of $37.20 million for the quarter, compared to analyst estimates of $36.30 million. Analysts forecast that Gyre Therapeutics, Inc. will post -0.3 earnings per share for the current fiscal year.
Insider Activity
In related news, CEO Ying Luo sold 10,136 shares of the stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $8.04, for a total value of $81,493.44. Following the transaction, the chief executive officer directly owned 2,565,226 shares in the company, valued at $20,624,417.04. This trade represents a 0.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 10.00% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Gyre Therapeutics
A number of large investors have recently modified their holdings of GYRE. Geode Capital Management LLC lifted its holdings in shares of Gyre Therapeutics by 28.6% in the 2nd quarter. Geode Capital Management LLC now owns 401,709 shares of the company’s stock worth $2,953,000 after purchasing an additional 89,390 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Gyre Therapeutics by 37.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company’s stock worth $1,194,000 after purchasing an additional 45,772 shares in the last quarter. Millennium Management LLC bought a new position in shares of Gyre Therapeutics in the 3rd quarter worth $267,000. State Street Corp lifted its stake in Gyre Therapeutics by 10.7% during the 4th quarter. State Street Corp now owns 202,225 shares of the company’s stock valued at $1,428,000 after acquiring an additional 19,472 shares in the last quarter. Finally, Lazard Asset Management LLC purchased a new position in Gyre Therapeutics during the 3rd quarter worth $111,000. 23.99% of the stock is currently owned by institutional investors.
About Gyre Therapeutics
Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.
Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.
Featured Stories
- Five stocks we like better than Gyre Therapeutics
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
- Cisco’s Vertical Rally May Still Be in the Early Innings
- Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
